Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022
Jounce Therapeutics, Inc. (NASDAQ: JNCE) has announced it will report its third quarter 2022 financial results and provide a corporate update on November 10, 2022. The event will feature a live conference call and webcast at 8:00 a.m. ET. Jounce is focused on developing cancer immunotherapies and predictive biomarkers, with ongoing development programs including its leading candidates JTX-8064 and vopratelimab. These therapies aim to enhance the immune system's ability to fight tumors, showcasing Jounce’s commitment to innovative cancer treatment.
- Ongoing development of JTX-8064 and vopratelimab indicates strong pipeline potential.
- Focus on cancer immunotherapies aligns with current industry trends toward personalized medicine.
- None.
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022. Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m. ET.
Conference Call and Webcast
To access the conference call, please register here and please be advised to do so at least 10 minutes prior to joining the call. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.jouncetx.com. The webcast will be archived and made available for replay on the company’s website approximately two hours after the call and will be available for 30 days thereafter.
About Jounce Therapeutics:
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and may provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. JTX-8064 is currently being investigated alone and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, in one monotherapy and seven indication-specific combination therapy cohorts in the Phase 1/2 INNATE trial and is currently enrolling patients with advanced solid tumors in the Phase 2 portion of the study. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to GS-1811 (formerly JTX-1811), a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
Investor and Media Contacts:
Eric Laub
Jounce Therapeutics, Inc.
+1-857-259-3853
elaub@jouncetx.com
FAQ
What is the date for Jounce Therapeutics' Q3 2022 financial results release?
What time is the Jounce Therapeutics conference call scheduled for?
What is the focus of Jounce Therapeutics' research and development?
Which key candidates are being developed by Jounce Therapeutics?
